Provided by Tiger Fintech (Singapore) Pte. Ltd.

EyePoint

10.42
+0.12001.17%
Post-market: 10.420.00000.00%17:29 EDT
Volume:725.51K
Turnover:7.62M
Market Cap:717.02M
PE:-4.30
High:10.80
Open:10.51
Low:10.28
Close:10.30
Loading ...

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Jul

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
16 Jul

EyePoint Pharmaceuticals Inc. Conducted Annual Stockholders Meeting

Reuters
·
20 Jun

EyePoint initiated with an Outperform at RBC Capital

TIPRANKS
·
17 Jun

RBC Capital Initiates EyePoint Pharmaceuticals at Outperform With $28 Price Target

MT Newswires Live
·
17 Jun

EyePoint reports inducement grants under NASDAQ listing rule

TIPRANKS
·
16 Jun

EyePoint Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 Jun

EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.

Dow Jones
·
30 May

EyePoint Pharmaceuticals (EYPT) Receives a Buy from Mizuho Securities

TIPRANKS
·
29 May

J.P. Morgan Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
28 May

BRIEF-Eyepoint Completes Enrollment In Pivotal Phase 3 Lugano Trial Of Duravy For Treatment Of Wet Age-Related Macular Degeneration

Reuters
·
27 May

EyePoint Completes Enrollment for DURAVYU Phase 3 Trial

TIPRANKS
·
27 May

EyePoint Pharmaceuticals Inc - Lucia Phase 3 Trial Expected to Complete Enrollment in 3Q 2025

THOMSON REUTERS
·
27 May

EyePoint Completes Enrollment in Pivotal Phase 3 Lugano Trial of Duravyu™ for Treatment of Wet Age-Related Macular Degeneration

THOMSON REUTERS
·
27 May

Karen L. Zaderej, Director, Reports Acquisition of Common Shares in EyePoint Pharmaceuticals Inc

Reuters
·
20 May

Mizuho Cuts Price Target on EyePoint Pharmaceuticals to $26 From $30, Keeps Outperform Rating

MT Newswires Live
·
16 May

BRIEF-Eyepoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
16 May

EyePoint Pharmaceuticals Inc : Mizuho Cuts Target Price to $26 From $30

THOMSON REUTERS
·
16 May

EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
16 May

Mizuho Securities Remains a Buy on EyePoint Pharmaceuticals (EYPT)

TIPRANKS
·
16 May